Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Opiant Pharmaceuticals Inc. (OPNT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 23,370
  • Shares Outstanding, K 2,050
  • Annual Sales, $ 9,900 K
  • Annual Income, $ -7,810 K
  • 36-Month Beta 1.10
  • Price/Sales 1.89
  • Price/Cash Flow 0.00
  • Price/Book 4.35
  • Price/Earnings ttm 3.60
  • Earnings Per Share ttm 2.54
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 06/14/17
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.3500 +160.65%
on 06/29/17
14.2500 -2.14%
on 07/27/17
+8.2900 (+140.43%)
since 06/27/17
3-Month
5.0000 +178.90%
on 06/16/17
14.2500 -2.14%
on 07/27/17
+7.5400 (+112.90%)
since 04/27/17
52-Week
5.0000 +178.90%
on 06/16/17
14.2500 -2.14%
on 07/27/17
+6.3900 (+81.10%)
since 07/27/16

Most Recent Stories

More News
Opiant CEO Roger Crystal Appears on Fox & Friends

Opiant Pharmaceuticals, Inc. ("Opiant") (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and eating disorders, today announced that Roger Crystal, M.D.,...

OPNT : 13.9450 (+22.32%)
Opiant Pharmaceuticals, Inc. Announces Phase I Data for OPNT002 in Development for the Treatment of Alcohol Use Disorder

Intravail Increased the Rate of Absorption of Intranasal Naltrexone

OPNT : 13.9450 (+22.32%)
Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing for New NARCAN(R) Nasal Spray Patent

Opiant Pharmaceuticals, Inc. ("Opiant") (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and eating disorders, today announced that its most recently...

OPNT : 13.9450 (+22.32%)
Opiant Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2017 Financial Results and Provides Corporate Update

Opiant Pharmaceuticals, Inc. ("Opiant") (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and eating disorders, today reported financial results for...

OPNT : 13.9450 (+22.32%)
Opiant Pharmaceuticals, Inc. Announces Initiation of Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa

Opiant Pharmaceuticals, Inc. ("Opiant") (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that the Company has initiated a Phase 2 clinical...

OPNT : 13.9450 (+22.32%)
Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listings for Two New NARCAN(R) Nasal Spray Patents

Opiant Pharmaceuticals, Inc. ("Opiant") (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that its most recently issued U.S. patents,...

OPNT : 13.9450 (+22.32%)
Opiant Pharmaceuticals, Inc. Receives FDA Feedback Supporting Clinical Development of OPNT002 for the Treatment of Alcohol Use Disorder

Opiant Pharmaceuticals, Inc. ("Opiant") (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that the Company has received supportive feedback...

OPNT : 13.9450 (+22.32%)
Opiant Pharmaceuticals, Inc. Announces Establishment of Audit, Compensation and Nominating and Corporate Governance Committees

Opiant Pharmaceuticals, Inc. ("Opiant") (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, today announced that the...

OPNT : 13.9450 (+22.32%)
Opiant Pharmaceuticals, Inc. Announces FDA Approval of 2mg Formulation of NARCAN (naloxone HCI) Nasal Spray

Opiant Pharmaceuticals, Inc. ("Opiant") (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, today announced that the...

OPNT : 13.9450 (+22.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is in the Top 1%. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Support & Resistance

2nd Resistance Point 13.4667
1st Resistance Point 12.4333
Last Price 13.9450
1st Support Level 9.9333
2nd Support Level 8.4667

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.